123 related articles for article (PubMed ID: 33769609)
1. CDKN2A deregulation in fatty liver disease and its accelerative role in the process of lipogenesis.
Zhang Z; Wen H; Peng B; Weng J; Zeng F
FASEB J; 2021 Apr; 35(4):e21230. PubMed ID: 33769609
[TBL] [Abstract][Full Text] [Related]
2. Silencing miR-181b-5p upregulates PIAS1 to repress oxidative stress and inflammatory response in rats with alcoholic fatty liver disease through inhibiting PRMT1.
Wang W; Zhong GZ; Long KB; Liu Y; Liu YQ; Xu AL
Int Immunopharmacol; 2021 Dec; 101(Pt B):108151. PubMed ID: 34836796
[TBL] [Abstract][Full Text] [Related]
3. A role for protein inhibitor of activated STAT1 (PIAS1) in lipogenic regulation through SUMOylation-independent suppression of liver X receptors.
Zhang Y; Gan Z; Huang P; Zhou L; Mao T; Shao M; Jiang X; Chen Y; Ying H; Cao M; Li J; Li J; Zhang WJ; Yang L; Liu Y
J Biol Chem; 2012 Nov; 287(45):37973-85. PubMed ID: 22969086
[TBL] [Abstract][Full Text] [Related]
4. PRMT1-mediated arginine methylation of PIAS1 regulates STAT1 signaling.
Weber S; Maass F; Schuemann M; Krause E; Suske G; Bauer UM
Genes Dev; 2009 Jan; 23(1):118-32. PubMed ID: 19136629
[TBL] [Abstract][Full Text] [Related]
5. Thioredoxin-interacting protein mediates hepatic lipogenesis and inflammation via PRMT1 and PGC-1α regulation in vitro and in vivo.
Park MJ; Kim DI; Lim SK; Choi JH; Kim JC; Yoon KC; Lee JB; Lee JH; Han HJ; Choi IP; Kim HC; Park SH
J Hepatol; 2014 Nov; 61(5):1151-7. PubMed ID: 25003952
[TBL] [Abstract][Full Text] [Related]
6. The SUMO E3-ligase PIAS1 couples reactive oxygen species-dependent JNK activation to oxidative cell death.
Leitao BB; Jones MC; Brosens JJ
FASEB J; 2011 Oct; 25(10):3416-25. PubMed ID: 21676946
[TBL] [Abstract][Full Text] [Related]
7. PIASy-mediated sumoylation of SREBP1c regulates hepatic lipid metabolism upon fasting signaling.
Lee GY; Jang H; Lee JH; Huh JY; Choi S; Chung J; Kim JB
Mol Cell Biol; 2014 Mar; 34(6):926-38. PubMed ID: 24379443
[TBL] [Abstract][Full Text] [Related]
8. Specific regulation of PRMT1 expression by PIAS1 and RKIP in BEAS-2B epithelia cells and HFL-1 fibroblasts in lung inflammation.
Liu L; Sun Q; Bao R; Roth M; Zhong B; Lan X; Tian J; He Q; Li D; Sun J; Yang X; Lu S
Sci Rep; 2016 Feb; 6():21810. PubMed ID: 26911452
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylation of protein inhibitor of activated STAT1 (PIAS1) by MAPK-activated protein kinase-2 inhibits endothelial inflammation via increasing both PIAS1 transrepression and SUMO E3 ligase activity.
Heo KS; Chang E; Takei Y; Le NT; Woo CH; Sullivan MA; Morrell C; Fujiwara K; Abe J
Arterioscler Thromb Vasc Biol; 2013 Feb; 33(2):321-9. PubMed ID: 23202365
[TBL] [Abstract][Full Text] [Related]
10. The arginine methyltransferase PRMT5 and PRMT1 distinctly regulate the degradation of anti-apoptotic protein CFLAR
Li M; An W; Xu L; Lin Y; Su L; Liu X
J Exp Clin Cancer Res; 2019 Feb; 38(1):64. PubMed ID: 30736843
[TBL] [Abstract][Full Text] [Related]
11. MiR-150 deficiency ameliorated hepatosteatosis and insulin resistance in nonalcoholic fatty liver disease via targeting CASP8 and FADD-like apoptosis regulator.
Zhuge B; Li G
Biochem Biophys Res Commun; 2017 Dec; 494(3-4):687-692. PubMed ID: 29107687
[TBL] [Abstract][Full Text] [Related]
12. Protein inhibitor of activated STAT1 Ser
Liu SY; Ma YL; Hsu WL; Chiou HY; Lee EHY
Br J Pharmacol; 2019 Jun; 176(11):1793-1810. PubMed ID: 30849179
[TBL] [Abstract][Full Text] [Related]
13. Protein Inhibitor of Activated STAT 1 (PIAS1) Protects Against Obesity-Induced Insulin Resistance by Inhibiting Inflammation Cascade in Adipose Tissue.
Liu Y; Ge X; Dou X; Guo L; Liu Y; Zhou SR; Wei XB; Qian SW; Huang HY; Xu CJ; Jia WP; Dang YJ; Li X; Tang QQ
Diabetes; 2015 Dec; 64(12):4061-74. PubMed ID: 26324179
[TBL] [Abstract][Full Text] [Related]
14. Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates.
Wang PX; Ji YX; Zhang XJ; Zhao LP; Yan ZZ; Zhang P; Shen LJ; Yang X; Fang J; Tian S; Zhu XY; Gong J; Zhang X; Wei QF; Wang Y; Li J; Wan L; Xie Q; She ZG; Wang Z; Huang Z; Li H
Nat Med; 2017 Apr; 23(4):439-449. PubMed ID: 28218919
[TBL] [Abstract][Full Text] [Related]
15. Silibinin ameliorates hepatic lipid accumulation and oxidative stress in mice with non-alcoholic steatohepatitis by regulating CFLAR-JNK pathway.
Liu Y; Xu W; Zhai T; You J; Chen Y
Acta Pharm Sin B; 2019 Jul; 9(4):745-757. PubMed ID: 31384535
[TBL] [Abstract][Full Text] [Related]
16. PIAS1 Alleviates Hepatic Ischemia-Reperfusion Injury in Mice through a Mechanism Involving NFATc1 SUMOylation.
Luo J; Li J; Li T; Zhang Z; Chen G; Li Q; Qi H; Si Z
Dis Markers; 2022; 2022():4988539. PubMed ID: 36092961
[TBL] [Abstract][Full Text] [Related]
17. Honokiol Alleviates Methionine-Choline Deficient Diet-Induced Hepatic Steatosis and Oxidative Stress in C57BL/6 Mice by Regulating CFLAR-JNK Pathway.
Zhai T; Xu W; Liu Y; Qian K; Xiong Y; Chen Y
Oxid Med Cell Longev; 2020; 2020():2313641. PubMed ID: 33354276
[TBL] [Abstract][Full Text] [Related]
18. mTOR regulates PRMT1 expression and mitochondrial mass through STAT1 phosphorylation in hepatic cell.
Zhang X; Li L; Li Y; Li Z; Zhai W; Sun Q; Yang X; Roth M; Lu S
Biochim Biophys Acta Mol Cell Res; 2021 May; 1868(6):119017. PubMed ID: 33741434
[TBL] [Abstract][Full Text] [Related]
19. Novel role and mechanism of protein inhibitor of activated STAT1 in spatial learning.
Tai DJ; Hsu WL; Liu YC; Ma YL; Lee EH
EMBO J; 2011 Jan; 30(1):205-20. PubMed ID: 21102409
[TBL] [Abstract][Full Text] [Related]
20. WISP1 promotes non-alcoholic fatty liver disease and skeletal muscle insulin resistance via TLR4/JNK signaling.
Jung TW; Kang C; Goh J; Chae SI; Kim HC; Lee TJ; Abd El-Aty AM; Jeong JH
J Cell Physiol; 2018 Aug; 233(8):6077-6087. PubMed ID: 29319180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
